Nothing said here yet.
to join the conversation.
| Stipancich John KEVP, Chief Legal Officer & Sec | Sell | 3,500 | $1.6M | Mon, Oct 26 |
| Conley JasonEVP, Chief Financial Officer | Sell | 10,105 | $4.4M | Fri, Oct 23 |
| Conley JasonEVP, Chief Financial Officer | Sell | 1,469 | $640.5K | Fri, Oct 23 |
| Conley JasonEVP, Chief Financial Officer | Sell | 426 | $184.8K | Fri, Oct 23 |
| Gilbert Cisneros | Sell | $8.0K | Fri, May 15 | Fri, Jun 5 |
| Gilbert Cisneros | Buy | $8.0K | Tue, Apr 14 | Thu, May 7 |
Roche Holding (SWX:ROP) has rolled out its VENTANA BAP1 (SP527) immunohistochemistry test worldwide, giving pathologists a highly specific tool to help distinguish malignant mesothelioma from other cancers using limited tissue samples.
Roper Technologies reported third quarter 2026 sales of US$2,171.8 million and net income of US$484.7 million, with GAAP diluted EPS from continuing operations of US$4.88.
Roper Technologies (ROP) is back in focus after releasing third quarter results showing higher sales, earnings and per share profits, alongside fresh guidance for the fourth quarter and full year 2026.
With $6 billion in deployment capacity and mid-90s software retention, Roper has both the firepower and the moat to compound shareholder returns through disciplined M&A.
Roche Holding has delivered a strong multi year share price run, helped by a busy drug pipeline and fresh clinical data. This raises a simple question for you as an investor: Is the current price still aligned with what the business is earning today?
Roper Technologies has rallied sharply in recent weeks, which puts the focus squarely on whether the current share price lines up with what its cash flows can justify.
Adjusted earnings rose 15% to $5.89 a share, beating expectations.
Software momentum drove 7% organic growth as management raised full-year guidance.